# Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

> **NCT04588324** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SHR2150
- **DRUG:** Anti-Cancer Agent
- **DRUG:** SHR2150

## Key facts

- **NCT ID:** NCT04588324
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-10
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588324, "Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04588324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*